Digoxin promotes anoikis of circulating cancer cells by targeting Na+/K+-ATPase α3-isoform

Yoshihisa Numata1, Takuto Fujii2, Chihiro Toda3

  • 1Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, 930-0194, Japan.

PubMed

Insights

Na+/K+-ATPase α3-isoform (α3NaK) in circulating cancer cells (CCCs) promotes survival by preventing anoikis. Digoxin inhibits α3NaK, enhancing anoikis and reducing metastasis in gastric cancer.

Area of Science:

  • Oncology
  • Cell Biology
  • Biochemistry

Background:

  • Circulating cancer cells (CCCs) are crucial for distant metastasis.
  • CCCs must evade anoikis (detachment-induced cell death) to survive.
  • The role of Na+/K+-ATPase α3-isoform (α3NaK) in CCC survival and anoikis evasion is unclear.

Purpose of the Study:

  • To investigate the role of α3NaK in anoikis evasion of CCCs.
  • To determine if targeting α3NaK can reduce metastasis in gastric cancer.

Main Methods:

  • Analysis of α3NaK localization in CCCs from gastric cancer patients.
  • Inhibition of α3NaK activity and translocation using digoxin in MKN45 cells.
  • Assessment of caspase activity and cell viability in detached cells.
  • Evaluation of digoxin's effect on CCCs and liver metastasis in a xenograft mouse model.

Main Results:

  • α3NaK localized to the plasma membrane in CCCs, translocating to the cytoplasm upon attachment.
  • Digoxin inhibited α3NaK activity and translocation without affecting α1NaK.
  • Digoxin increased caspase activity and reduced viability of detached cells.
  • Digoxin administration reduced CCCs and liver metastasis in vivo.

Conclusions:

  • α3NaK is essential for CCC survival by preventing anoikis in gastric cancer.
  • Digoxin enhances anoikis in detached gastric cancer cells by inhibiting α3NaK translocation.
  • Targeting α3NaK represents a potential therapeutic strategy against CCC survival and metastasis.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
440
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.6K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K